Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.

Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K, Slack GW, Abou Mourad Y, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Sanford DS, Sutherland HJ, Tucker T, Toze CL, Sehn LH, Broady R, Gerrie AS.

Br J Haematol. 2018 Jun;181(6):782-790. doi: 10.1111/bjh.15262. Epub 2018 May 9.

PMID:
29741758
2.

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia.

Lai D, Chen M, Su J, Liu X, Rothe K, Hu K, Forrest DL, Eaves CJ, Morin GB, Jiang X.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaan8735. doi: 10.1126/scitranslmed.aan8735.

PMID:
29437150
3.

A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.

Liu X, Rothe K, Yen R, Fruhstorfer C, Maetzig T, Chen M, Forrest DL, Humphries RK, Jiang X.

Leukemia. 2017 Nov;31(11):2376-2387. doi: 10.1038/leu.2017.108. Epub 2017 Apr 3.

4.

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.

Nair AP, Barnett MJ, Broady RC, Hogge DE, Song KW, Toze CL, Nantel SH, Power MM, Sutherland HJ, Nevill TJ, Abou Mourad Y, Narayanan S, Gerrie AS, Forrest DL.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1437-44. doi: 10.1016/j.bbmt.2015.04.005. Epub 2015 Apr 10.

5.

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.

Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):341-8. doi: 10.1016/j.clml.2014.12.015. Epub 2015 Jan 3.

PMID:
25656914
6.

The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells.

Rothe K, Lin H, Lin KB, Leung A, Wang HM, Malekesmaeili M, Brinkman RR, Forrest DL, Gorski SM, Jiang X.

Blood. 2014 Jun 5;123(23):3622-34. doi: 10.1182/blood-2013-07-516807. Epub 2014 Apr 22.

7.

Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.

J Natl Cancer Inst. 2013 Mar 20;105(6):405-23. doi: 10.1093/jnci/djt006. Epub 2013 Feb 27.

8.

Normal karyotype CALLA-positive adult pre-B ALL: dismal outcome with chemotherapy for patients with loss/gain of ABL1 and/or BCR FISH signals.

Abou Mourad YR, Bhargava R, Bruyère H, Gillian T, Barnett MJ, Forrest DL, Nevill TJ, Toze CL, Nantel SH, Shepherd JD.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):281-6. doi: 10.1016/j.clml.2012.09.007. Epub 2012 Oct 24.

PMID:
23098889
9.

Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.

Toze CL, Dalal CB, Nevill TJ, Gillan TL, Abou Mourad YR, Barnett MJ, Broady RC, Forrest DL, Hogge DE, Nantel SH, Power MM, Song KW, Sutherland HJ, Smith CA, Narayanan S, Young SS, Connors JM, Shepherd JD.

Br J Haematol. 2012 Jul;158(2):174-185. doi: 10.1111/j.1365-2141.2012.09170.x. Epub 2012 May 29.

PMID:
22640008
10.

Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy.

Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL.

Leuk Lymphoma. 2012 Jul;53(7):1321-6. doi: 10.3109/10428194.2011.652108. Epub 2012 Mar 5.

PMID:
22192245
11.

Disseminated mucormycosis presenting as transplant-associated thrombotic microangiopathy.

Peterson EA, Gerrie AS, Power MM, Poulin MP, Dalal BI, Forrest DL.

Leuk Res. 2011 Jul;35(7):e138-40. doi: 10.1016/j.leukres.2011.03.003. Epub 2011 Apr 22. No abstract available.

PMID:
21514669
12.

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).

Venner CP, Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, Toze CL, Smith CA, Song KW.

Leuk Lymphoma. 2011 Jan;52(1):34-41. doi: 10.3109/10428194.2010.531409. Epub 2010 Dec 6.

PMID:
21133716
13.

Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.

Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL.

Biol Blood Marrow Transplant. 2010 May;16(5):639-46. doi: 10.1016/j.bbmt.2009.11.026. Epub 2010 Feb 4.

14.

Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.

Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Lavoie JC.

Bone Marrow Transplant. 2010 Feb;45(2):295-302. doi: 10.1038/bmt.2009.128. Epub 2009 Jul 13.

PMID:
19597425
15.

IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.

Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA.

Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13. doi: 10.1016/j.bbmt.2008.11.015.

16.

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.

Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y, Smith CA.

Leuk Res. 2009 Feb;33(2):271-5. doi: 10.1016/j.leukres.2008.07.015. Epub 2008 Aug 31.

PMID:
18762338
17.

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.

Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, Jackson SC, Poon MC, Sinclair GD, Leber B, Johnson PR, Macheta A, Yin JA, Barnett MJ, Lister TA, Fitzgibbon J.

Blood. 2008 Dec 1;112(12):4639-45. doi: 10.1182/blood-2008-05-156745. Epub 2008 Aug 21.

18.

Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results.

Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, Nevill TJ, Shepherd JD, Nantel SH, Sutherland HJ, Forrest DL, Hogge DE, Lavoie JC, Abou-Mourad YR, Chhanabhai M, Voss NJ, Brinkman RR, Smith CA, Toze CL.

Bone Marrow Transplant. 2008 Nov;42(9):601-8. doi: 10.1038/bmt.2008.220. Epub 2008 Aug 11.

PMID:
18695664
19.

Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.

Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA.

Bone Marrow Transplant. 2008 Nov;42(10):659-66. doi: 10.1038/bmt.2008.226. Epub 2008 Aug 4.

PMID:
18679372
20.

An approach to the management of chronic myeloid leukemia in British Columbia.

Forrest DL, Jiang X, Eaves CJ, Smith CL.

Curr Oncol. 2008 Apr;15(2):90-7.

21.

Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.

Gallagher G, Horsman DE, Tsang P, Forrest DL.

Cancer Genet Cytogenet. 2008 Feb;181(1):46-51. doi: 10.1016/j.cancergencyto.2007.10.021.

PMID:
18262053
22.

Serotonin syndrome after concomitant treatment with linezolid and meperidine.

Das PK, Warkentin DI, Hewko R, Forrest DL.

Clin Infect Dis. 2008 Jan 15;46(2):264-5. doi: 10.1086/524671.

PMID:
18171260
23.

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.

Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. Epub 2007 May 29.

24.

Readers' perspectives. The recent revisions to federal rules to permit information technology donations to physicians will help spur I.T. adoption. Do you agree or disagree?

Shutt S, Tague RD, Jensen M, Forrest DL, Hartz C.

Health Data Manag. 2007 Apr;15(4):64. No abstract available.

PMID:
17500246
25.

Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia.

Halim TY, Song KW, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC.

Ann Oncol. 2007 Jul;18(7):1246-52. Epub 2007 Apr 17.

PMID:
17442662
26.

Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.

Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM.

Ann Oncol. 2007 Mar;18(3):535-40. Epub 2006 Dec 8.

PMID:
17158775
27.

Recommendations of the canadian consensus group on the management of chronic myeloid leukemia.

Laneuville P, Barnett MJ, Bélanger R, Couban S, Forrest DL, Roy DC, Lipton JH.

Curr Oncol. 2006 Dec;13(6):201-21.

28.

Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation.

Dalal BI, Horsman DE, Bruyèrè H, Forrest DL.

Am J Hematol. 2007 Jan;82(1):77-9. No abstract available.

29.

Second solid cancers after allogeneic hematopoietic stem cell transplantation.

Gallagher G, Forrest DL.

Cancer. 2007 Jan 1;109(1):84-92.

30.

Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.

Lin Y, Bruyère H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL.

Cancer Genet Cytogenet. 2006 Oct 1;170(1):16-23.

PMID:
16965950
31.

Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia.

Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, Forrest DL, Horsman DE, Smith C, Song K, Sutherland HJ, Toze CL, Nevill TJ, Nantel SH, Hogge DE.

Leuk Lymphoma. 2006 Jul;47(7):1245-52.

PMID:
16923553
32.

Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.

Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL, Connors JM.

Br J Haematol. 2006 Jun;133(6):634-7.

PMID:
16704438
33.

Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.

Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ.

Biol Blood Marrow Transplant. 2006 Apr;12(4):480-9.

34.

Shifting to outpatient management of acute myeloid leukemia: a prospective experience.

Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC.

Ann Oncol. 2006 May;17(5):763-8. Epub 2006 Feb 23.

PMID:
16497826
35.

High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.

Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM.

J Clin Oncol. 2005 Nov 1;23(31):7994-8002. Epub 2005 Oct 3.

PMID:
16204014
36.

Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.

Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW.

Br J Haematol. 2005 Oct;131(2):223-30.

PMID:
16197454
37.

Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.

Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J.

Bone Marrow Transplant. 2005 Nov;36(9):825-30.

PMID:
16151430
38.

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission.

Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M, Keating A.

Leuk Lymphoma. 2005 Apr;46(4):525-31.

PMID:
16019480
39.

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ.

Blood. 2005 Aug 15;106(4):1473-8. Epub 2005 May 3.

40.

Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation.

Toze CL, Barnett MJ, Connors JM, Gascoyne RD, Voss NJ, Nantel SH, Nevill TJ, Shepherd JD, Sutherland HJ, Lavoie JC, Forrest DL, Song KW, Hogge DE.

Br J Haematol. 2004 Nov;127(3):311-21.

PMID:
15491292
41.

Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation.

Kuruvilla J, Forrest DL, Lavoie JC, Nantel SH, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ.

Bone Marrow Transplant. 2004 Dec;34(11):969-73.

PMID:
15489882
42.

Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.

Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA; Canadian PRCA Focus Group.

J Am Soc Nephrol. 2004 Oct;15(10):2728-34.

43.

Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21).

Khoury H, Dalal BI, Nantel SH, Horsman DE, Lavoie JC, Shepherd JD, Hogge DE, Toze CL, Song KW, Forrest DL, Sutherland HJ, Nevill TJ.

Mod Pathol. 2004 Oct;17(10):1211-6.

44.

Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation.

El-Seisi S, Gupta R, Clase CM, Forrest DL, Milandinovic M, Couban S.

Biol Blood Marrow Transplant. 2003 Nov;9(11):683-8.

45.

Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.

Forrest DL, Nevill TJ, Naiman SC, Le A, Brockington DA, Barnett MJ, Lavoie JC, Nantel SH, Song KW, Shepherd JD, Sutherland HJ, Toze CL, Davis JH, Hogge DE.

Bone Marrow Transplant. 2003 Nov;32(9):915-23.

PMID:
14561993
46.
47.

Constitutional rearrangements of 7q22 in hematologic malignancies. a new case report.

Forrest DL, Lee CL.

Cancer Genet Cytogenet. 2002 Nov;139(1):75-7.

PMID:
12547165
48.

Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma.

Forrest DL, Thompson K, Nevill TJ, Couban S, Fernandez LA.

Bone Marrow Transplant. 2002 Jun;29(12):973-8.

49.

Myelodysplastic syndrome and a nonrandom chromosomal abnormality t(1;19): an indolent pathologic entity.

Forrest DL, Couban S, Nevill TJ, Lee CY, Welch PJ.

Cancer Genet Cytogenet. 2000 Oct 15;122(2):134-6.

PMID:
11106825
50.

Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients.

Couban S, Messner HA, Andreou P, Egan B, Price S, Tinker L, Meharchand J, Forrest DL, Lipton J.

Biol Blood Marrow Transplant. 2000;6(4A):422-7.

PMID:
10975510

Supplemental Content

Loading ...
Support Center